Abstract
Aberrant gene expression is characteristic to all cancer cells and pathophysiology in general. Selective inhibition of constitutively elevated expression of oncogenes provides an opportunity to hinder the proliferation of malignant cells. Small synthetic molecules that specifically interfere with transcription and/or translation have great potential as anticancer drugs. Currently first-generation antisense oligonucleotides are widely used to inhibit the oncogene expression. The second generation of antisense agents have been studied mainly in vitro. One of these agents, peptide nucleic acid (PNA) is an oligonucleotide mimic with a noncharged achiral polyamide backbone to which the nucleobases are linked. PNA oligomers bind tightly to complementary DNA or RNA and are very stable in biological fluids. PNA can inhibit transcription and translation of target genes by specifically hybridizing to DNA or mRNA. The in vitro experiments showing inhibition of target protein expression by PNA have been followed by the first successful applications of PNA as an antisense agent in cultured cells and also in vivo. Hopefully this will lead to a wider use of PNA in the studies of cancer biology and therapy.
Current Cancer Drug Targets
Title: Targeting of Cancer-Related Proteins with PNA Oligomers
Volume: 1 Issue: 3
Author(s): Margus Pooga and Ulo Langel
Affiliation:
Abstract: Aberrant gene expression is characteristic to all cancer cells and pathophysiology in general. Selective inhibition of constitutively elevated expression of oncogenes provides an opportunity to hinder the proliferation of malignant cells. Small synthetic molecules that specifically interfere with transcription and/or translation have great potential as anticancer drugs. Currently first-generation antisense oligonucleotides are widely used to inhibit the oncogene expression. The second generation of antisense agents have been studied mainly in vitro. One of these agents, peptide nucleic acid (PNA) is an oligonucleotide mimic with a noncharged achiral polyamide backbone to which the nucleobases are linked. PNA oligomers bind tightly to complementary DNA or RNA and are very stable in biological fluids. PNA can inhibit transcription and translation of target genes by specifically hybridizing to DNA or mRNA. The in vitro experiments showing inhibition of target protein expression by PNA have been followed by the first successful applications of PNA as an antisense agent in cultured cells and also in vivo. Hopefully this will lead to a wider use of PNA in the studies of cancer biology and therapy.
Export Options
About this article
Cite this article as:
Margus Pooga and Ulo Langel , Targeting of Cancer-Related Proteins with PNA Oligomers, Current Cancer Drug Targets 2001; 1 (3) . https://dx.doi.org/10.2174/1568009013334142
DOI https://dx.doi.org/10.2174/1568009013334142 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Current Molecular Pharmacology Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design Design, Synthesis and In Vitro Anticancer Activity of a New Class of Bifunctional DNA Intercalators
Letters in Drug Design & Discovery Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma
Current Gene Therapy Antimicrobial Peptides in Oral Cancer
Current Pharmaceutical Design Phytosynthesized Nanoparticles for Effective Cancer Treatment: A Review
Nanoscience & Nanotechnology-Asia α,β-Acetylenic Amino Thiolester Inhibitors of Aldehyde Dehydrogenases 1&3: Suppressors of Apoptogenic Aldehyde Oxidation and Activators of Apoptosis
Current Medicinal Chemistry Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
Anti-Cancer Agents in Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy